secwatch.observer — SEC 8-K summary
======================================

Issuer:     Finch Therapeutics Group, Inc. (FNCHQ)
CIK:        0001733257
Form:       8-K
Filed at:   2023-01-24T23:59:59+00:00
Accession:  0000950170-23-001046
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.05, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Finch Therapeutics ends Phase 3 CP101 trial, cuts 95% of staff to focus on IP monetization
--------------------------------------------------------------------------------

- Discontinued PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection; cites capital outlook, slow enrollment, unauthorized IP use.
- Workforce reduced by 77 employees (~95% of employee base); most roles end Feb 2023, some continued into May 2023.
- Expected restructuring costs of approximately $4.1 million from severance, outplacement and related expenses; charges recorded in H1 2023.
- Company holds over 70 issued U.S. and foreign patents microbiome therapeutics and will seek to realize value from its IP estate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023001046/0000950170-23-001046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1733257/000095017023001046/fnch-20230123.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-001046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer